Weeks after Sun Pharmaceutical completed its acquisition of troubled Ranbaxy Laboratories, 18 top execs have reportedly been given their pink slips. The Economic Times reports that executives let go include President and CFO Indrajit Banerjee and Yugal Sikri, who headed operations in India. A source said another 150 executives would be terminated as the company continues its integration. Sun has said its top priority is to restore the rights of four Ranbaxy plants now banned by the FDA to ship products to the U.S. Story | More